Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression.
Anxiety
CCTR
Cannabis
Depression
EMBASE
Insomnia
MASCC
MEDLINE
PsychINFO databases
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
21 Feb 2023
21 Feb 2023
Historique:
received:
13
10
2022
accepted:
02
02
2023
entrez:
22
2
2023
pubmed:
23
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
During the treatment of cancer, 18% of patients use cannabis for symptom management. Anxiety, depression, and sleep disturbances are common symptoms in cancer. A systematic review of the evidence for cannabis use for psychological symptoms in cancer patients was undertaken to develop a guideline. A literature search of randomized trials and systematic reviews was undertaken up to November 12, 2021. Studies were independently assessed for evidence by two authors and then evaluated by all authors for approval. The literature search involved MEDLINE, CCTR, EMBASE, and PsychINFO databases. Inclusion criteria included randomized control trials and systematic reviews on cannabis versus placebo or active comparator in patients with cancer and psychological symptom management (anxiety, depression, and insomnia). The search yielded 829 articles; 145 from Medline, 419 from Embase, 62 from PsychINFO, and 203 from CCTR. Two systematic reviews and 15 randomized trials (4 on sleep, 5 on mood, 6 on both) met eligibility criteria. However, no studies specifically assessed the efficacy of cannabis on psychological symptoms as primary outcomes in cancer patients. The studies varied widely in terms of interventions, control, duration, and outcome measures. Six of 15 RCTs suggested benefits (five for sleep, one for mood). There is no high-quality evidence to recommend the use of cannabis as an intervention for psychological symptoms in patients with cancer until more high-quality research demonstrates benefit.
Identifiants
pubmed: 36809575
doi: 10.1007/s00520-023-07628-3
pii: 10.1007/s00520-023-07628-3
doi:
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
176Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Martell K, Fairchild A, LeGerrier B et al (2018) Rates of cannabis use in patients with cancer. Curr Oncol 25:219–225
pubmed: 29962840
pmcid: 6023560
doi: 10.3747/co.25.3983
Kaul M, Zee PC, Sahni SA (2021) Effects of cannabinoids on sleep and their therapeutic potential for sleep disorders. Neurotherapeutics 18:217–227
pubmed: 33580483
pmcid: 8116407
doi: 10.1007/s13311-021-01013-w
Daris B, Verboten MT, Knez Z et al (2019) Cannabinoids in cancer treatment: therapeutic potential and legislation. Bosn J Basic Med Sci 19:14–23
pubmed: 30172249
pmcid: 6387667
doi: 10.17305/bjbms.2018.3532
Pawasarat IM, Schultz EM, Firsby JC et al (2020) The efficacy of medical marijuana in the treatment of cancer-related pain. J Palliat Med 23:809–816
pubmed: 32101075
doi: 10.1089/jpm.2019.0374
Sarfaraz S, Afaq F, Adhami VM et al (2005) Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65:1635–1641
pubmed: 15753356
doi: 10.1158/0008-5472.CAN-04-3410
Bar-Sela G, Avisar A, Batash R et al (2014) Is the clinical use of cannabis by oncology patients advisable? Curr Med Chem 21:1923–1930
pubmed: 24606496
doi: 10.2174/0929867321666140304151323
Caputo PM, Rodriguez CS, Padhya TA et al (2021) Medical cannabis as adjunctive therapy for head and neck cancer patients. Cureus 13:e18396
pubmed: 34729274
pmcid: 8555939
Babson KA, Sottile J, Morabito D (2017) Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry 19:23
doi: 10.1007/s11920-017-0775-9
Shannon S, Lewis N, Lee H et al (2019) Cannabidiol in anxiety and sleep: a large case series. Perm J 23:18–041
pubmed: 30624194
pmcid: 6326553
doi: 10.7812/TPP/18-041
Suraev AS, Marshall NS, Vandrey R (2020) Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies. Sleep Med Rev 53:101339
pubmed: 32603954
doi: 10.1016/j.smrv.2020.101339
Cotè M, Trudel M, Wang C et al (2016) Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-double blind placebo-controlled trial. Ann Otol Rhinol Laryngol 125:317–324
pubmed: 26503964
doi: 10.1177/0003489415612801
Fallon MT, Lux EA, McQuade R et al (2017) Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain 11:119–133
pubmed: 28785408
pmcid: 5521351
doi: 10.1177/2049463717710042
Lichtman AH, Lux EA, McQuade R et al (2018) Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage 55:179-188.e1
pubmed: 28923526
doi: 10.1016/j.jpainsymman.2017.09.001
Zylla DM, Eklund J, Gilmore G et al (2021) A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer 29:7471–7478
pubmed: 34085149
doi: 10.1007/s00520-021-06301-x
Hauser W, Welsch P, Klose P et al (2019) Efficacy, tolerability and safety of cannabis-based medicines for cancer pain. A systematic review with meta-analysis of randomized controlled trials. Schmerts 33:424–436
doi: 10.1007/s00482-019-0373-3
Johnson JR, Burnell-Nugent M, Lossignol D et al (2010) Multicenter, double-blind, randomized. Placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of the THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39:167–179
pubmed: 19896326
doi: 10.1016/j.jpainsymman.2009.06.008
Portenoy RK, Ganae-Montan ED, Allende S et al (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13:438–449
pubmed: 22483680
doi: 10.1016/j.jpain.2012.01.003
Ungerleider JT, Andrysiak T, Fairbanks L et al (1982) Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 50:636–645
pubmed: 6284334
doi: 10.1002/1097-0142(19820815)50:4<636::AID-CNCR2820500404>3.0.CO;2-4
Ungerleider JT, Fairbanks LA, Andrysiak T et al (1985) THC or Compazine for the cancer chemotherapy patient-the UCLA study. Part II: patient drug preference. Am J Clin Onco 8:142–147
doi: 10.1097/00000421-198504000-00006
Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a north central cancer treatment group study. J Clin Oncol 20:567–573
pubmed: 11786587
doi: 10.1200/JCO.2002.20.2.567
Strasser LD, Possinger K et al (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24:3394–3400
pubmed: 16849753
doi: 10.1200/JCO.2005.05.1847
Lynch ME, Cesar-Rittenberg P, Hohmann AG (2014) A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 47:166–173
pubmed: 23742737
doi: 10.1016/j.jpainsymman.2013.02.018
Johnson JR, Lossignol D, Burnell-Nugent M et al (2013) An open-label extension study to investigate the long-term safety and tolerability of the THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 46:207–218
pubmed: 23141881
doi: 10.1016/j.jpainsymman.2012.07.014
Brisbois TD, de Kock IH, Watanabe SM et al (2011) Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22:2086–2093
pubmed: 21343383
doi: 10.1093/annonc/mdq727
Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D et al (2018) The effect of nabilone on appetite, nutritional status and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer 26:3029–3038
pubmed: 29550881
doi: 10.1007/s00520-018-4154-9
Schloss J, Lacey J, Sinclair J et al (2021) A phase 2 randomized clinical trial assessing the tolerability of two different ratios of medical cannabis in patients with high grade gliomas. Front Oncol 11:649555. https://doi.org/10.3389/fonc.2021.649555
doi: 10.3389/fonc.2021.649555
pubmed: 34094937
pmcid: 8176855
Whiting PF, Wolff RF, Deshpande S et al (2015) Cannabinoids for medical use. Syst Rev Meta-Anal JAMA 313:2456–2473
Russo EB (2011) Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163:1344–1364
pubmed: 21749363
pmcid: 3165946
doi: 10.1111/j.1476-5381.2011.01238.x
Bhattacharyya S, Wilson R, Appiah-Kusi E et al (2018) Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at high risk of psychosis: a randomized clinical trial. JAMA Psychiat 75:1107–1117
doi: 10.1001/jamapsychiatry.2018.2309
Murillo-Rodrìguez E (2008) The role of CB1 receptor in the regulation of sleep. Prog Neuropsychopharmacol Biol Psychiatry 32:1420–1427
pubmed: 18514375
doi: 10.1016/j.pnpbp.2008.04.008
Bitencourt RM, Takahashi RN (2018) Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: from bench research to confirmation in human trials. Front Neurosci 12:502
pubmed: 30087591
pmcid: 6066583
doi: 10.3389/fnins.2018.00502
Spindle TR, Cone EJ, Goffi E et al (2020) Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend 211:107937
pubmed: 32247649
pmcid: 7414803
doi: 10.1016/j.drugalcdep.2020.107937
Sarris J, Sinclair J, Karamacoska D et al (2020) Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry 20:24. https://doi.org/10.1186/s12888-019-2409-8
doi: 10.1186/s12888-019-2409-8
pubmed: 31948424
pmcid: 6966847
Walsh Z, Gonzalez R, Crosby K et al (2017) Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev 51:15–29
pubmed: 27816801
doi: 10.1016/j.cpr.2016.10.002
Botsford SL, Yang S, George TP (2020) Review: cannabis and cannabinoids in mood and anxiety disorder: impact on illness onset and course, and assessment of therapeutic potential. Am J Addict 29(1):9–26
pubmed: 31577377
doi: 10.1111/ajad.12963
Gage SH, Hickman M, Zammit S (2016) Association between cannabis and psycosis:epidemiologic evidence. Biol Psychiatry 79:549–556
pubmed: 26386480
doi: 10.1016/j.biopsych.2015.08.001
Leweke FM, Piomelli D, Phlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94
pubmed: 22832859
pmcid: 3316151
doi: 10.1038/tp.2012.15
McGuire P, Robson P, Jerzy Cubala W et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225–231
pubmed: 29241357
doi: 10.1176/appi.ajp.2017.17030325
Boggs DL, Surti T, Gupta A et al (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 235:1923–1932
pubmed: 29619533
doi: 10.1007/s00213-018-4885-9
Cooper RE, Williams E, Seegobin S et al (2017) Cannabinoids in attention-deficit/hyperactivity disorder: a randomized-controlled trial. Eur Neuropsychopharmacol 27:795–808
pubmed: 28576350
doi: 10.1016/j.euroneuro.2017.05.005
Gibbs M, Winsper C, Marwaha S (2015) Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord 171:39–47
pubmed: 25285897
doi: 10.1016/j.jad.2014.09.016
Zuardi A, Crippa J, Dursun SM et al (2010) Cannabidiol was ineffective for manic episode of bipolar affective disorders. J Psychopharmacol 24:135–137
pubmed: 18801823
doi: 10.1177/0269881108096521
Jetly R, Heber A, Fraser G et al (2015) The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51:585–588
pubmed: 25467221
doi: 10.1016/j.psyneuen.2014.11.002
Cameron EC, Hemingway SL (2020) Cannabinoids for fibromyalgia pain: a critical review of recent studies (2015–2019). J Cannabis Res 2:19
pubmed: 33526114
pmcid: 7819299
doi: 10.1186/s42238-020-00024-2
Khurshid H, Qureshi IA, Jahan N et al (2021) A systematic review of fibromyalgia and recent advancements in treatment: is medicinal cannabis a new hope? Cureus 13:e17332
pubmed: 34567876
pmcid: 8451533
Giossi R, Carrara F, Padroni M et al (2022) Systematic review and meta-analysis seem to indicate that cannabinoids for chronic primary pain treatment have limited benefit. Pain Ther 11:1341–1358
pubmed: 36129666
pmcid: 9633894
doi: 10.1007/s40122-022-00434-5
Kosiba JD, Maisto SA, Ditre JW (2019) Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis. Soc Sci Med 233:181–192
pubmed: 31207470
doi: 10.1016/j.socscimed.2019.06.005
Allsop JD, Copeland J, Lintzeris N et al (2014) Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiat 71:281–291
doi: 10.1001/jamapsychiatry.2013.3947
Podda G, Constantinescu CS (2012) Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis. Expert Opin Biol Ther 12:1517–1531
pubmed: 22954177
doi: 10.1517/14712598.2012.721765
Trigo JM, Soliman A, Quilty LC et al (2018) Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLoS One 13:e0190768
pubmed: 29385147
pmcid: 5791962
doi: 10.1371/journal.pone.0190768
Sharpe L, Sinclair J, Kramer A et al (2020) Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med 18:374
pubmed: 33008420
pmcid: 7531079
doi: 10.1186/s12967-020-02518-2
Hitchcock L. Anxiety, inflammation and stress. 2018. Available from https://clinicaltrials.gov/ct2/show/NCT03491384?cond=Anxiety&intr=Cannabis&rank=2
ACTRN12617000825358 (2021) The cannabidiol youth anxiety pilot study (CAPS):a 12-week open label pilot study of the safety, tolerability and efficacy of cannabidiol for anxiety disorders. https://clinicaltrials.gov/ct2/show/NCT03549819
Kedzior KK, Laeber LT (2014) A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population–a meta-analysis of 31 studies. BMC Psychiatry 14:136
pubmed: 24884989
pmcid: 4032500
doi: 10.1186/1471-244X-14-136
Saugy M, Avois L, Saudan C et al (2006) Cannabis and sport. Br J Sports Med 40(Suppl 1):i13-15
pubmed: 16799094
pmcid: 2657492
doi: 10.1136/bjsm.2006.027607
Choi S, Huan BC, Gamaldo CE (2020) Therapeutic use of cannabis on sleep disorders and related conditions. J Clin Neurophysiol 37:39–49
pubmed: 31895189
doi: 10.1097/WNP.0000000000000617
Degenhardt L, Wayne H, Lynskey M (2003) Exploring the association between cannabis use and depression. Addiction 98:1493–1504
pubmed: 14616175
doi: 10.1046/j.1360-0443.2003.00437.x
Moore THM, Zammit S, Lingford-Hughes A (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328
pubmed: 17662880
doi: 10.1016/S0140-6736(07)61162-3
Conroy DA, Kurth ME, Strong DR et al (2016) Marijuana use patterns and sleep among community-based young adults. J Addict Dis 35:135–143
pubmed: 26727193
pmcid: 4911998
doi: 10.1080/10550887.2015.1132986
Ergisi M, Erridge S, Harris M et al (2022) UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder. Expert Rev Clin Pharmacol 18:1–9
Bergamaschi MM, Queiroz RG, Chagas MH et al (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36:1219–1226
pubmed: 21307846
pmcid: 3079847
doi: 10.1038/npp.2011.6
Crippa JA, Derenusson GN, Ferrari TB et al (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 25:121–130
pubmed: 20829306
doi: 10.1177/0269881110379283
Ware NA, Fitzcharles MA, Lawrence J (2020) The effect of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 110:604–610
doi: 10.1213/ANE.0b013e3181c76f70
Gross H, Michael E, Faden V et al (1983) A double-blind trial of □9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psyhopharmacol 3:167–171
AminiLari M, Wang L, Neumark S et al (2021) Medical cannabis for impaired sleep: a systematic review and meta-analysis of randomized clinical trials. Sleep zsab234. https://doi.org/10.1093/sleep/zsab234
Walsh JH, Maddison KJ, Rankin T et al (2021) Treating insomnia symptoms with medical cannabis: a randomizes, crossover trial of the efficacy of a cannabinoid medicine compared to placebo. Sleep 44:zssab149
doi: 10.1093/sleep/zsab149
Suraev A, Grunstein RR, Marshall NS et al (2020) Cannabidiol (CBD) and □9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for randomized, placebo-controlled, double-blinded, proof-of-concept trial. BMJ open 10(5):e034421. https://doi.org/10.1136/bmjopen-2019-034421
doi: 10.1136/bmjopen-2019-034421
pubmed: 32430450
pmcid: 7239553
Palmieri G, Vadalà M, Corazzari V et al (2022) Insomnia treatment: a new multitasking natural compound based on melatonin and cannabis extracts. Clin Ter 173:91–96
pubmed: 35147654
Almogi-Hazan O, Or R (2020) Cannabis, the endocannabinoid system and immunity-the journey from the bedside to the bench and back. Int J Mol Sci 21:4448
pubmed: 32585801
pmcid: 7352399
doi: 10.3390/ijms21124448